This collaboration will enable clinical trial sponsors to quantify the histological effects of compounds and gain deeper insight into underlying mechanisms in MASH-targeted therapies using state-of-the-art spatial transcriptomics and AI-powered single-fiber and single-cell digital pathology.

Dr. Peter A. Schneider, Professor of Surgery at University of California, San Francisco and Member of the TRANSCEND Trial Steering Committee, will present the TRANSCEND trial’s safety and efficacy data through 36 months as part of a November 15, 2023 session focused on randomized controlled trial (RCT) updates on new developments in drug coated balloons (DCBs) and drug eluting stents (DESs).

NICO Corporation notes the proof-of-concept study was published in Brain-Computer Interfaces in September and used a modified and miniaturized NICO BrainPath, the world’s first navigated trans-sulcal access technology widely used in Minimally Invasive Parafascicular Surgery (MIPS) for access in the removal of brain tumors and evacuation of hemorrhagic stroke.

Obesity remains a pressing global health concern, with the World Obesity Federation projecting potential economic impacts exceeding $4 trillion by 2035. TCI’s innovative technology represents a proactive response to this challenge and offers consumers a natural and powerful weight management solution. The company’s strides are expected to drive a transformative shift in the health industry’s approach to combating obesity.

he study met its primary endpoint of target lesion failure (TLF) with no TLF events reported in the study arm, demonstrating safety compared to DES. The data were presented by Stefan Verheye, M.D., Ph.D., Interventional Cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium and the study co- principal investigator at the Innovation Program session at the Transcatheter Cardiovascular Therapeutics (TCT) conference today in San Francisco.